MET and lung carcinoma: The HGF receptor, cMet, is highly expressed in various solid tumor indications (Giordano et al., 1992; Isaksson‐Mettavainio et al., 2008; Sierra and Tsao, 2011; Yap et al., 2011), and mutations in the MET gene (Pilotto et al., 2017) (e.g., exon 14 splice variant: NSCLC 3–10%, gastric 7.1%) and gene amplifications are relatively rare (Jardim et al., 2015) (6% gastric cancer, 1% lung cancer).